Experience with ponatinib in paediatric patients with leukaemia
Jenna Rossoff, Van Huynh, Rachel E. Rau, Margaret E. Macy, Maria Luisa Sulis, Kirk R. Schultz, Michael J. Burke, Uma H. Athale, Maureen M. O’Brien, John Gregory, Inge M. van der Sluis, Frank G. Keller, C. Michel Zwaan, Meinolf Suttorp, Nobuko Hijiya
Abstract
Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. Among paediatric patients with chronic myeloid leukaemia (n = 9) or acute lymphoblastic leukaemia (n = 12) treated with varying doses of ponatinib in 13 centres, 71% showed a decrease in disease burden after a median of three months. Ponatinib was well tolerated, with grade 3 toxicities occurring in 29% of patients. Toxicities were similar to those reported in adults, with the exception of arterial thrombotic events, which were not observed. Ponatinib has a favourable safety profile in this paediatric cohort, but dose-finding studies are needed.